AngioDynamics Announces Launch of the TOTAL ABSCESSION General Drainage Catheter
The TOTAL ABSCESSION catheter features a tamper-resistant locking mechanism known as the VAULT. This unique feature eliminates additional procedures to replace drainage catheters when the locking pigtail shape becomes unlocked during routine catheter maintenance. The VAULT reduces physician time and increases patient comfort.
The TOTAL ABSCESSION catheter permits aspiration while the pigtail is in either the locked or unlocked position, allowing the physician accuracy in placement and greater versatility for draining complex situations.
"The VAULT locking mechanism represents significant value to both physicians and patients in terms of decreasing physician time and improving patient comfort," commented Eamonn P. Hobbs, president and chief executive officer of AngioDynamics. "TOTAL ABSCESSION reflects our continued dedication and commitment to providing new, innovative and proven solutions to our physician customers and we are very excited that this catheter is now available worldwide."
Al Concemi, product manager for drainage products, remarked, "The physician response to the TOTAL ABSCESSION catheter has been remarkable during our test market. The VAULT locking mechanism was well received and is seen as a clear improvement over existing devices. The TOTAL ABSCESSION is another example of our ability to innovate and bring value-added products to the market."
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, results of pending patent litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company.
CONTACT: AngioDynamics, Inc.
Al Concemi, 800-772-6446 x385
aconcemi@angiodynamics.com
http://www.angiodynamics.com/
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
SOURCE: AngioDynamics, Inc.